| October 6, 2025 | Regulated Bioanalysis Workshop | |
| October 7, 2025 | Discovery Bioanalysis and New Technologies Workshop | |
| October 8, 2025 | Mechanistic ADME Workshop |
Regulated Bioanalysis Workshop - Monday, October 6, 2025
|
Title |
Speaker |
Company |
Time |
|
Registration, Breakfast, Exhibits |
|
7:30 - 8:30 |
|
|
Workshop Introduction. |
Nevena Mollova |
Gilead |
8:30 - 8:40 |
|
Session I: Precision Strategies in Regulated BA & Biomarker Validation |
|||
|
Session Introduction: Darshana Jani, Moderna; Ang Liu, Johnson & Johnson; Nevena Mollova, Gilead |
|
|
8:40 - 8:45 |
|
PK Cross Validation: Past, Present, Future |
Patrick Breslin |
J & J |
8:45 - 9:05 |
|
Metabolite Bioanalysis in Drug Development: Recommendations From the IQ Consortium Metabolite Bioanalysis Working Group |
Wenkui Liu |
Novartis |
9:05 - 9:25 |
|
Oversight of Bioavailability and Bioequivalence Studies in Support of New and Generic Drugs and Therapeutic Biologics |
Sean Kassim |
FDA |
9:25 - 9:45 |
|
Biomarker Validation in Clinical Drug Development 2025 |
Lindsay King |
Pfizer |
9:45 - 10:05 |
|
TBA |
TBA |
TBA |
10:05 - 10:25 |
|
AM Break & Exhibits |
|
|
10:25 - 10:45 |
|
Sponsor Presentation: Application of LC-MS/MS Methods for Characterization of Low-abundance Peptides, Proteins, and Biomarkers in Biological Samples |
Jason Hamilton |
|
10:45 - 11:00 |
|
Session II: Analytical Innovations in Emerging Modalities & Nucleic Acid-Based Therapies |
|||
|
Session Introduction: Seema Kumar, Flagship & Jennifer Cunliffe, Novartis |
|
|
11:00 - 11:05 |
|
Identification of Critical Reagents for Novel Biotherapeutic Modalities: Considerations and Case Studies |
Krisna Duong-Ly |
Merck |
11:05 - 11:30 |
|
Characterization of Critical Reagents with Different New Modalities |
Rosmery Lawrence-Henderson |
Pfizer |
11:30 - 11:55 |
|
Unraveling xRNA Immunogenicity: Insights and Future Horizons |
Maria Jadhav |
Novartis |
11:55 - 12:20 |
|
Lunch, Exhibits, and Poster Viewing (1:10 pm - 1:30 pm) |
|
12:30 - 1:30 |
|
|
Vendor Presentation: Title TBA |
TBA |
|
1:30 - 1:45 |
|
Session III: Immunogenicity Matters: Advances in ADA Assay Development and Monitoring |
|||
|
Session Introduction: Fumin Li, Unitides Bioanalytical Lab & James Schiller, Merck |
|
1:45 - 1:50 |
|
|
Signal-to-Noise Ratio: A Streamlined Alternative to Titer for Anti-Drug Antibody Assessment |
Amy Li |
Genentech |
1:50 - 2:15 |
|
Bioanalytical Immunogenicity Strategy for the Clesrovimab Program: A Case Study |
Brad Roadcap |
Merck |
2:15 - 2:40 |
|
When Singlicate and Duplicate Diverge: Evaluating Risk, Performance, and Feasibility in Ligand Binding Assays |
Douglas Donaldson |
Moderna |
2:40 - 3:05 |
|
Clinical Immunogenicity Monitoring of an Fc Fusion Protein Drug with Two Endogenous Counterparts: From Screening to Domain Specificity and Cross-Reactivity |
Jinsong Yang |
Keros |
3:05 - 3:30 |
|
PM Break & Exhibits |
|
|
3:30 - 3:50 |
|
Session IV: Beyond Buzzwords: Real-World AI and ML Applications in Bioanalysis |
|||
|
Session Introduction: |
|
|
3:50 - 3:55 |
|
Machine Learning Guided Selection of Chiral Supercritical Fluid Chromatography Conditions |
Kiyoto Tanemura |
BMS |
3:55 - 4:15 |
|
Leveraging AI in Bioanalysis: Real-World Applications of Large Language Models |
Stephanie Pasas-Farmer |
BioData Solutions |
4:15 - 4:35 |
|
Exploration of AI and ML-Powered Models for Predicting Immunogenicity in Preclinical Tox Studies |
Afsana Trini |
BMS |
4:35 - 4:55 |
|
Session V: Innovation Junction: Bridging Science and Solutions in Pharma |
|||
|
Sponsor Showcase: TBA |
|
|
4:55 - 5:15 |
|
Session VI: Rapid Fire Poster Presentations |
|||
|
Session Introduction: |
|
5:15 - 5:20 |
|
|
Poster Presenters: 1. TBD 2. TBD 3. TBD 4. TBD |
|
|
5:20 - 5:40 |
| Sciex's User Meeting & Reception |  |
||
Discovery Bioanalysis and New Technologies Workshop - Tuesday, October 7, 2025
|
Title |
Speaker |
Company |
Time |
|
Registration, Breakfast, Exhibits |
|
7:30 - 8:30 |
|
|
Workshop Introduction |
|
|
8:30 - 8:35 |
|
Session I: Bioanalytical Challenges and Approaches for Oligonucleotides in Therapeutic Development |
|||
|
Session Introduction: Jing Tu, GSK; Linlin Dong, Takeda; Hongying Gao, Innovo Bioanalysis |
|
|
8:35 - 8:40 |
|
Novel LBA Methodology for Bioanalysis of Antibody-siRNA Drug Conjugates |
Diana Cha |
Alnylam |
8:40 - 9:05 |
|
LC-MS Bioanalytical Support for Oligonucleotide PK/PD Studies |
John Chen |
NovaBioAssays |
9:05 - 9:30 |
|
Bridging HELISA and LC-MS for Quantification of siRNA and Its Metabolite in Preclinical Studies |
Yunlin Fu |
Novartis |
9:30 - 9:55 |
|
Sponsor Presentation: Title TBA |
TBA |
|
9:55 - 10:10 |
|
AM Break & Exhibits |
|
10:10 - 10:40 |
|
|
Session II: Immunogenicity & ADA Assessment |
|||
|
Session Introduction: John Williams, Vertex & Ju Liu, Eli Lilly |
|
|
10:40 - 10:45 |
|
MHC-associated Peptide Proteomics (MAPPS) Assay for Characterization of Presented Peptide Epitopes |
Emilee Knowlton |
PepImmune |
10:45 - 11:10 |
|
Immunogenicity Risk Assessment at the pre-IND Stage: Integrated Immunogenicity Risk Assessment in Protein-based Biotherapeutic Drug Development |
Xiaobin Zhang |
Takeda |
11:10 - 11:35 |
|
Overcoming Challenges Associated with Anti-drug Antibody (ADA) Assay Development for Antisense Oligonucleotides (ASOs) |
Brittany Youngs |
Stoke Therapeutics |
11:35 - 12:00 |
|
In Silico Immunogenicity Risk Assessments: AI- Enhanced Prediction of Clinical Immunogenicity Outcomes with EpiVax’s ISPRI Toolkit |
Aimee Mattei |
EpiVax |
12:00 - 12:25 |
|
Lunch, Exhibits, and Poster Viewing |
|
12:25 - 1:40 |
|
|
Sponsor Presentation: Title TBA |
TBA |
|
1:40 - 1:50 |
|
Session III: AI & Machine Learning in Bioanalysis and Drug Discovery |
|||
|
Session Introduction: Yu Tian, AbbVie & Zachary Parsons, BMS |
|
|
1:50 - 1:55 |
|
Plenary Talk: Title TBA |
Gary Jenkins |
AbbVie |
1:55 - 2:35 |
|
Basics of Machine Learning and Its Applications in Drug Discovery |
Reilly Eason |
Merck |
2:35 - 3:00 |
|
Leveraging AI in Computational Toxicology |
Wei Liang |
AbbVie |
3:00 - 3:25 |
|
Session IV: Complex Biologics & Bioanalytical Strategies & Biomarker Analysis and Applications in Drug Development |
|||
|
Session Introduction: Jonathan Joseph & Paddy Eangoor, Sanofi |
|
3:25 - 3:30 |
|
|
A Two-Cycle Immunoaffinity Enrichment Strategy with Acid Treatment to Enhance Biotherapeutics Assay Sensitivity in Tissues |
Yipei Zhang |
Takeda |
3:30 - 4:00 |
|
PM Break & Exhibits |
|
4:00 - 4:20 |
|
|
Strategic Bioanalytical Approaches for Complex Biologics: Tools and Case Studies |
Paddy Eangoor |
Sanofi |
4:20 - 4:50 |
|
Rapid Fire Talks |
|
|
4:50 - 5:15 |
|
Reception & Exhibits |
|
5:15 - 6:30 |
|
Mechanistic ADME Workshop - Wednesday, October 8, 2025
|
Title |
Speaker |
Company |
Time |
|
Registration, Breakfast, Exhibits |
|
7:30 - 8:30 |
|
|
Workshop Introduction |
|
|
8:30 - 8:40 |
|
Plenary Talk - Human Mass Balance and Metabolite Profiling Studies: Regulatory Guidance, Technical Approaches and Clinical Implications |
Chandra Prakash |
Agios |
8:40 - 9:20 |
|
Session I: PROTACs and Molecular Glues with respect to ADME challenges and human PK/dose projection; Early dose prediction strategies |
|||
|
Session Introduction: Raman Sharma, Pfizer; Sara Shum, City Therapeutics & Hongbin Yu, Boehringer-Ingelheim |
9:40 - 9:25 |
||
|
Title TBA |
Mark Niosi |
Pfizer |
9:25 - 9:50 |
|
ADME profiling of clinical stage PROTACs |
Jesse Yu |
Relay Therapeutics |
9:50 - 10:15 |
|
Mathematical Modeling for Human Dose Prediction of Degraders |
Jan Elias |
Boehringer-Ingelheim |
10:15 - 10:40 |
|
AM Break & Exhibits |
|
|
10:40 - 11:05 |
|
Rapid Fire Poster Presentations 1. TBD 2. TBD 3. TBD 4. TBD |
|
|
11:05 - 11:25 |
|
Session II: Use of AI & ML for Early Dose Prediction and ADME Properties |
|||
|
Session Introduction: Christopher Kochansky, Exelixis; Donglu Zhang, Genentech & April Chen, AstraZeneca |
|
11:25 - 11:30 |
|
|
Title TBA |
Kaushik Mitra |
J & J |
11:30 - 11:55 |
|
Scoring Success in Molecule Making - From Idea Generation to PK Candidate Selection |
Fabio Broccatelli |
Altos Labs |
11:55 - 12:20 |
|
AI-aided drug design from drug metabolism perspectives |
Lionel Cheruzel |
Genentech |
12:20 - 12:45 |
|
Lunch, Exhibits, and Poster Viewing |
|
12:45 - 2:00 |
|
|
Session III: New Insights on the Discovery and Characterization of Covalent Inhibitors |
|||
|
Session Introduction: Benjamin Johnson, BMS & David Stresser, AbbVie |
|
|
2:00 - 2:05 |
|
DMPK Considerations for the Development of Targeted Covalent Inhibitor Drugs: An IQ Consortium Assessment |
Martin Dowty |
AbbVie |
2:05 - 2:30 |
|
Analytical Strategies for Covalent Drug Discovery - Targeting Residues Beyond Cysteine |
Lyn Jones |
Harvard University |
2:30 - 3:05 |
|
PM Break & Exhibits |
|
|
3:05 - 3:25 |
|
GSH Conjugation in a Covalent Drug Discovery Paradigm: The Untold GST Story |
Cody Fullendwider |
Vividion Therapeutics |
3:25 - 3:50 |
|
Session IV: Recent Progress on Understanding Mechanisms of Hepatotoxicity |
|||
|
Session Introduction: James Driscoll; Nagendra Chemuturi, Eli Lilly & Eric Ballard, Takeda |
|
|
3:50 - 3:55 |
|
Covalent Protein Modifications By Reactive Metabolites: Evidence For Drug-Induced Liver Toxicity |
Qinying Yu |
Genentech |
3:55 - 4:20 |
|
Title TBA |
Matthew Wagoner |
Takeda |
4:20 - 4:45 |
|
Conference Closing Remarks |
|
4:45- 4:50 |
|